Key Takeaways VKTX to report Q4 results with no revenues expected and a consensus loss of 89 cents per share.VKTX completed VANQUISH-1 enrollment for VK2735, VANQUISH-2 to complete enrollment later in 2026.Further updates on obesity, NASH, and X-ALD programs are expected during the Q4 earnings call.We expect investors to focus on Viking Therapeutics’ (VKTX) progress with the development of its lead candidate, VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic ...